Literature DB >> 11300694

Inhibition of human telomerase by 7-deaza-2'-deoxyguanosine nucleoside triphosphate analogs: potent inhibition by 6-thio-7-deaza-2'-deoxyguanosine 5'-triphosphate.

T M Fletcher1, B E Cathers, K S Ravikumar, B M Mamiya, S M Kerwin.   

Abstract

We have examined analogs of the previously reported 7-deaza-2'-deoxypurine nucleoside triphosphate series of human telomerase inhibitors. Two new telomerase-inhibiting nucleotides are reported: 6-methoxy-7-deaza-2'-deoxyguanosine 5'-triphosphate (OMDG-TP) and 6-thio-7-deaza-2'-deoxyguanosine 5'-triphosphate (TDG-TP). In particular, TDG-TP is a very potent inhibitor of human telomerase with an IC(50) of 60 nM. TDG-TP can substitute for dGTP as a substrate for telomerase, but only at relatively high concentrations. Under conditions in which TDG-TP is the only available guanosine substrate, telomerase becomes nonprocessive, synthesizing short products that appear to contain only one to three TDG residues. Similarly, the less potent telomerase inhibitor OMDG-TP gives rise to short telomerase products, but less efficiently than TDG-TP. We show here that TDG-TP, and to a lesser extent OMDG-TP, can serve as substrates for both templated (Klenow exo) and nontemplated (terminal transferase) DNA polymerases. For either polymerase, the products arising from TDG-TP are relatively short, and give rise to bands of unusual mobility under PAGE conditions. These anomalous bands revert, under treatment with DTT, to normal mobility bands, indicating that these products may contain thiol-labile disulfide linkages involving the incorporated TDG residues. This observation of potential TDG-crosslinks may have bearing on the mechanism of telomerase inhibition by this nucleotide analog. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11300694     DOI: 10.1006/bioo.2000.1194

Source DB:  PubMed          Journal:  Bioorg Chem        ISSN: 0045-2068            Impact factor:   5.275


  7 in total

Review 1.  Natural and pharmacological regulation of telomerase.

Authors:  Jean-Louis Mergny; Jean-François Riou; Patrick Mailliet; Marie-Paule Teulade-Fichou; Eric Gilson
Journal:  Nucleic Acids Res       Date:  2002-02-15       Impact factor: 16.971

2.  Design of Small Molecules That Compete with Nucleotide Binding to an Engineered Oncogenic KRAS Allele.

Authors:  Yan Zhang; Marie-Hélène Larraufie; Leila Musavi; Hemanth Akkiraju; Lewis M Brown; Brent R Stockwell
Journal:  Biochemistry       Date:  2018-02-06       Impact factor: 3.162

3.  Targeting human telomerase for cancer therapeutics.

Authors:  Lionel Guittat; Patrizia Alberti; Dennis Gomez; Anne De Cian; Gaëlle Pennarun; Thibault Lemarteleur; Chafke Belmokhtar; Rajaa Paterski; Hamid Morjani; Chantal Trentesaux; Eliane Mandine; François Boussin; Patrick Mailliet; Laurent Lacroix; Jean-François Riou; Jean-Louis Mergny
Journal:  Cytotechnology       Date:  2004-06       Impact factor: 2.058

Review 4.  Strategies targeting telomerase inhibition.

Authors:  Huaping Chen; Yuanyuan Li; Trygve O Tollefsbol
Journal:  Mol Biotechnol       Date:  2008-10-28       Impact factor: 2.695

5.  Structural Basis of Telomerase Inhibition by the Highly Specific BIBR1532.

Authors:  Christopher Bryan; Cory Rice; Hunter Hoffman; Michael Harkisheimer; Melanie Sweeney; Emmanuel Skordalakes
Journal:  Structure       Date:  2015-09-10       Impact factor: 5.006

Review 6.  Telomerase as a Cancer Target. Development of New Molecules.

Authors:  D L Mengual Gomez; R G Armando; C S Cerrudo; P D Ghiringhelli; D E Gomez
Journal:  Curr Top Med Chem       Date:  2016       Impact factor: 3.295

Review 7.  Structural Features of Nucleoprotein CST/Shelterin Complex Involved in the Telomere Maintenance and Its Association with Disease Mutations.

Authors:  Mohd Amir; Parvez Khan; Aarfa Queen; Ravins Dohare; Mohamed F Alajmi; Afzal Hussain; Asimul Islam; Faizan Ahmad; Imtaiyaz Hassan
Journal:  Cells       Date:  2020-02-04       Impact factor: 7.666

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.